Medistem Founder Panama granted U.S. patent on the owner of cancer based on the patient’s cells

I am grateful to the team of clinical and basic research who believed and supported our dream of using the cells of the body to heal, said Dr. Riordan. Our ongoing work in Panama Medistem with adult stem cells is a continuation of our work on dendritic cells, the only difference is that instead of using the body’s cells fight against cancer, we are using the body’s cells to fight degenerative diseases. Scientists at Jefferson Medical College has received a four-year, $ 3 million National Institutes of Health grant funded by the National Heart, Lung and Blood Institute to study the variations of platelet function, in particular, the genetics of gene expression in platelets. The study aims to find data that can be translated into new therapeutic strategies and develop better predictors of cardiovascular disease.

Dr. Riordan has established centers for the treatment of cancer with dendritic cell therapy a decade ago, but only this year did the FDA approve this initiative, said Thomas Ichim, CEO of Medistem Inc. The results obtained The innovative patent-pending attest to the successful integration of basic research and clinical practice that has been launched by the founder of Medistem Panama .

Medistem Panama is a biotechnology company located in Panama City, Panama, which has the isolation, manipulation, expansion and storage capacity. As owner of American society, Medistem Inc, is engaged in basic research and applications of umbilical cord blood, the matrix of the placenta, bone marrow and adipose-derived stem cells.

Medistem Panama regularly collaborates with scientists from leading universities in North America including the University of California at San Diego and the University of Western Ontario.